Breaking Finance News

Halozyme Therapeutics (NASDAQ:HALO) target price raised to $18.00, reported today by Piper Jaffray

Yesterday Halozyme Therapeutics (NASDAQ:HALO) traded 4.59% higher at $11.56. Halozyme Therapeutics’s 50-day average is $10.18 and its 200-day moving average is $9.69. With the last stock price close up 19.84% relative to the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. 1,481,729 shares of Halozyme Therapeutics traded hands, up from ann avg. trading volume of 1,227,840.

Halozyme Therapeutics (NASDAQ:HALO) had its price target bumped up to $18 by Piper Jaffray in a report issued 9/16/2016. The latest target price indicates a potential upside of 0.56% based on the company’s last stock close price.

Previously on 6/23/2015, JP Morgan released a statement on Halozyme Therapeutics(NASDAQ:HALO) bumped the target price from $20.00 to $25.00 that indicated a possible upside of 0.13%.

See Chart Below:

Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics has a 52 week low of $6.96 and a 52 week high of $19.63 and has a market cap of $0.0.

General Company Details For Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *